Arcutis Biotherapeutics Inc [NASDAQ: ARQT] traded at a high on Wednesday, posting a 8.36 gain after which it closed the day’ session at $13.22.
The results of the trading session contributed to over 3954585 shares changing hands. Over the past one week, the price volatility of Arcutis Biotherapeutics Inc stands at 7.95% while the volatility over the past one month is 8.02%.
The market cap for ARQT stock reached $1.55 billion, with 117.85 million shares outstanding and 103.03 million shares in the current float. Compared to the average trading volume of 2.15M shares, ARQT reached a trading volume of 3954585 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Arcutis Biotherapeutics Inc [ARQT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 30, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on August 28, 2024, representing the official price target for Arcutis Biotherapeutics Inc stock. Previously, the target price had yet another raise from $4 to $8, while Mizuho kept a Buy rating on ARQT stock. On October 26, 2023, analysts decreased their price target for ARQT shares from 57 to 4.
The Average True Range (ATR) for Arcutis Biotherapeutics Inc is set at 1.05, with the Price to Sales ratio for ARQT stock in the period of the last 12 months amounting to 7.87. The Price to Book ratio for the last quarter was 9.89, with the Price to Cash per share for the same quarter was set at 1.95.
How has ARQT stock performed recently?
Arcutis Biotherapeutics Inc [ARQT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.77. With this latest performance, ARQT shares dropped by -7.23% in over the last four-week period, additionally plugging by 34.49% over the last 6 months – not to mention a rise of 36.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 52.18, with the RSI for the last a single of trading hit 54.67, and the three-weeks RSI is set at 51.51 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 13.53, while it was recorded at 12.85 for the last single week of trading, and 10.63 for the last 200 days.
Arcutis Biotherapeutics Inc [ARQT]: Deeper insight into the fundamentals
Arcutis Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.97 and a Current Ratio set at 4.15.
Insider trade positions for Arcutis Biotherapeutics Inc [ARQT]
The top three institutional holders of ARQT stocks are: JENNISON ASSOCIATES LLC with ownership of 11.57 million shares, which is approximately 9.3712%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 10.0 million shares of the stock with an approximate value of $$93.04 million in ARQT stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$91.3 million in ARQT stock with ownership which is approximately 7.95%.
